Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities researchers at Raymond James lifted their Q1 2026 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a report issued on Monday, March 17th. Raymond James analyst M. Freeman now expects that the company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.26). Raymond James currently has a "Strong-Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals' FY2026 earnings at ($0.46) EPS.
Several other brokerages have also recently commented on MDP. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Stifel Nicolaus downgraded Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and reduced their target price for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th. Stifel Canada lowered Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 17th. Finally, Ventum Financial lifted their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a "buy" rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of C$5.49.
Read Our Latest Report on MDP
Medexus Pharmaceuticals Trading Down 2.5 %
TSE MDP traded down C$0.07 during trading hours on Wednesday, reaching C$2.70. 9,081 shares of the company traded hands, compared to its average volume of 133,422. The company has a 50 day moving average of C$3.33 and a two-hundred day moving average of C$2.92. The stock has a market capitalization of C$60.45 million, a PE ratio of 12.91 and a beta of 1.96. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$5.56.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
